MOXEZA Drug Patent Profile

Which patents cover Moxeza, and what generic alternatives are available?

Moxeza is a drug marketed by Harrow Eye and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has twenty-three patent family members in fifteen countries.

The generic ingredient in MOXEZA is moxifloxacin hydrochloride. There are eighteen drug master file entries for this compound. Thirty-five suppliers are listed for this compound. Additional details are available on the moxifloxacin hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Moxeza

A generic version of MOXEZA was approved as moxifloxacin hydrochloride by TEVA PHARMS USA on February 18^th, 2014.

Summary for MOXEZA

International Patents:	23
US Patents:	2
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	105
Clinical Trials:	1
Patent Applications:	2,264
Drug Prices:	Drug price information for MOXEZA
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for MOXEZA
What excipients (inactive ingredients) are in MOXEZA?	MOXEZA excipients list
DailyMed Link:	MOXEZA at DailyMed

See drug prices for MOXEZA

See drug sales revenues for MOXEZA

Recent Clinical Trials for MOXEZA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Usona Institute	Phase 1

See all MOXEZA clinical trials

Paragraph IV (Patent) Challenges for MOXEZA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
MOXEZA	Ophthalmic Solution	moxifloxacin hydrochloride	0.5%	022428	1	2012-02-29

US Patents and Regulatory Information for MOXEZA

MOXEZA is protected by two US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Harrow Eye	MOXEZA	moxifloxacin hydrochloride	SOLUTION/DROPS;OPHTHALMIC	022428-001	Nov 19, 2010		DISCN	Yes	No	9,114,168		Y
Harrow Eye	MOXEZA	moxifloxacin hydrochloride	SOLUTION/DROPS;OPHTHALMIC	022428-001	Nov 19, 2010		DISCN	Yes	No	8,450,311		Y

International Patents for MOXEZA

See the table below for patents covering MOXEZA around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	135354
Austria	292127
Australia	1028392
Australia	2528692
Australia	3659489
Australia	6055694

Supplementary Protection Certificates for MOXEZA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0350733	300111	Netherlands
0350733	SPC/GB03/034	United Kingdom		PRODUCT NAME: MOXIFLOXACIN AND PHARMACEUTICALLY USABLE HYDRATES AND ACID ADDITION SALTS THEREOF AND THE ALKALI METAL, ALKALINE EARTH METAL, SILVER AND GUANIDINIUM SALTS OF THE UNDERLYING CARBOXYLIC ACIDS AND THE RACEMATES THEREOF; REGISTERED: DE 45263.00.00 19990621; UK PL 000 10/0291 20030313
0350733	2001C/030	Belgium		PRODUCT NAME: MOXIFLOXACINE CHLORHYDRATE (CORRESPONDANT A MOXIFLOXACINE); NATL. REGISTRATION NO/DATE: 187 IS 328 F 3 20010507; FIRST REGISTRATION: DE 45263.00.00 19990621
0350733	11/2000	Austria		PRODUCT NAME: MOXIFLOXACIN, DESSEN PHARMAZEUTISCH VERWENDBARE HYDRATE UND SAEUREADDITIONSSALZE, DESSEN ALKALI-ERDALKALI-SILBER- UND GUANIDINIUMSALZE, SOWIE DESSEN C1 - C4 ALKYL- ODER; NAT. REGISTRATION NO/DATE: 1-23494, 1-23495, 1-23496 20000215; FIRST REGISTRATION: DE 45263.00.00 19990621
0350733	C300111	Netherlands		PRODUCT NAME: MOXIFLOXACINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER MOXIFLOXACINEHYDROCHLORIDE; NAT. REGISTRATION NO/DATE: RVG 28118 RVG 28119 20021017; FIRST REGISTRATION: DE 45263.00.00 19990621
0780390	PA2004012,C0780390	Lithuania		PRODUCT NAME: MOXIFLOXACINI HYDROCHLORIDUM (1-CIKLOPROPIL-6-FLUOR-1,4-DIHIDRO-8-METOKSI-7-((4AS, 7AS)-OKTAHIDRO-6H-PIROLO(3,4-B)PIRIDIN-6-IL)-4-OKSO-3-CHINOLINKARBOKSIRUGSTIES HIDROCHLORIDAS); REGISTRATION NO/DATE: 04/8383/3 20040309

MOXEZA (moxifloxacin ophthalmic solution): Market dynamics and financial trajectory

Last updated: April 24, 2026

What is MOXEZA and where does it sit commercially?

MOXEZA is a brand of moxifloxacin ophthalmic solution (antibiotic for ocular bacterial infections). Commercially, it competes in the U.S. ophthalmic antibiotic market where prescribers choose among fluoroquinolone eye drops, and where pricing and contracting determine profitability more than clinical differentiation.

MOXEZA’s market behavior is shaped by three fixed forces:

1. Class competition (other fluoroquinolone brands and generics)
2. Formulation and dosing convenience (once-daily regimens can win share)
3. Channel economics (wholesale pricing, WAC-to-NET compression, rebate pressure, and payer contracting)

How does MOXEZA’s market dynamics change with generics and contracting?

In ophthalmics, the generic substitution cycle hits fast after patent expiry and generic entry. Once generics are established, brand manufacturers usually respond with:

• Price concessions through rebates and trade terms
• Patient and prescriber pull via co-pay support (where allowed)
• Portfolio shifts to defend share where clinical pathways remain stable

The practical outcome for an Rx ophthalmic antibiotic brand like MOXEZA is typically NET revenue compression even when unit volume holds. That is driven by a lower achievable WAC and higher effective rebate rates required to maintain formulary position.

What is the competitive set that governs MOXEZA’s sales velocity?

MOXEZA’s performance depends on how it stacks up against other moxifloxacin-based and broader fluoroquinolone ophthalmics in:

• Efficacy category (clinician prescribing habits)
• Dosing frequency (adherence and office workflows)
• Formulary tiering (managed care)
• Availability of authorized generics and standard generics

Once a generic moxifloxacin product is fully entrenched, MOXEZA’s market position shifts from “choice” to “covered preferred” where rebate and contracting can keep it on formularies.

How do hospital/clinic buying patterns translate into brand-level financials?

Ophthalmic antibiotic prescribing often flows through:

• Retail pharmacy scripts
• Ocular procedure clinics (direct-to-patient dispensing or preferred sourcing)

These channels convert into financial outcomes through:

• Script volume vs. ASP/NAP erosion: units can remain stable while pricing drops
• Distribution constraints: shortages or supply reliability change fill rates
• Payer controls: prior authorization and step edits reduce marginal sales

For a brand like MOXEZA, the most important financial lever is effective net price, not list price, because rebate intensity rises when generics or competing brands discount to preserve share.

---

What financial trajectory does a MOXEZA-like ophthalmic brand typically follow?

The trajectory for a mature ophthalmic antibiotic brand usually moves through four phases:

1) Pre-generic intensity: growth or stable share with premium pricing

• Brand competes on dosing and physician preference
• Higher gross-to-net ratio

2) Generic entry: revenue peak transitions into net compression

• Brand unit share can erode gradually
• Net revenue per script declines faster than volume

3) Mature generic: stabilization at lower revenue base

• Brand survives on formulary placement, contracting, and co-pay programs
• Cost structure and SG&A become key for margin

4) Portfolio drift or discontinuation risk

• Brand may lose relevance if newer or more advantaged products win payer preference

MOXEZA’s financial shape follows this typical path because the competitive set is structurally similar: ophthalmic fluoroquinolones are substitutable and payers manage them tightly once generic availability expands.

---

What do patent and regulatory milestones imply for the revenue curve?

MOXEZA’s long-run revenue curve depends on:

• Exclusivity over moxifloxacin ophthalmic solution
• Patent coverage around formulation, method of use, and composition
• Orphaning of exclusivity by manufacturing and labeling

After exclusivity ends, generic manufacturing and ANDA submissions usually accelerate. The brand sees a lag between filing announcements and actual market share loss, but the earnings impact typically shows up in:

• ASP decline
• Gross-to-net deterioration
• Sustained volume loss or forced rebate escalation

---

How can investors and R&D leaders model MOXEZA’s financial trajectory without guesswork?

A robust modeling approach for a brand like MOXEZA is to anchor on net revenue drivers and map scenario changes around generic entry and contracting.

Core financial driver mapping for MOXEZA

Driver	What to watch	Financial impact
Net price (ASP/NAP proxy)	WAC-to-NET compression after competitive entrants	Revenue per script declines
Script volume	Share loss after generic uptake	Revenue falls with time lag
Formulary status	Tier placement and rebate required to remain preferred	Sustains or erodes volume
Channel mix	Retail vs clinic dispensing changes	Margin and working capital profile changes
Supply stability	Fill rate and backorders	Missed prescriptions reduce quarterly revenue

Scenario mechanics (high-level)

Scenario	When it hits	Typical outcome
Competitive shock (generic expansion)	Following market entry	Sharp net price drop; volume decline
Contract reset	Next contracting cycle	Rebate intensity rises; margins compress
Share stabilization	If formulary preference holds	Volume stabilizes; net revenue remains depressed
Portfolio replacement	If newer products win	Brand revenue declines without margin recovery

This framework converts market dynamics into a financial trajectory without relying on narrative.

---

What does this mean for profitability and cash flow?

For mature ophthalmic brands, cash flow usually comes under pressure when net price falls faster than variable cost can adjust. Key margin outcomes:

• Gross margin erosion: list-to-net compression and price concessions
• SG&A inefficiency: continued sales force and contracting costs even as share declines
• Working capital changes: distributor inventory behavior can affect quarter-to-quarter revenue recognition

A common pattern is that brand profitability declines after generic entry even if revenue falls more slowly at first, due to rebate rate changes and the cost to defend coverage.

---

What are the business implications for continuing MOXEZA’s presence?

The decision to defend or reduce brand investment depends on whether MOXEZA can:

• Maintain formulary coverage with acceptable rebate economics
• Offset generic share loss through co-pay support and prescriber reinforcement
• Manage supply risk and manufacturing costs during competitive pricing pressure

For manufacturers, the strategic question is less “can MOXEZA still sell” and more “can it sell profitably relative to the cost of defending coverage.”

---

Key Takeaways

• MOXEZA competes in a structurally substitutable category where pricing and rebates drive the financial trajectory after generic entry.
• Market dynamics shift from premium pricing to rebate-heavy coverage defense once generics and competing fluoroquinolones gain scale.
• Financial performance typically follows a predictable curve: net price compression precedes or outpaces volume erosion, pulling down margins and cash flow.
• Modeling should focus on net price drivers (ASP/NAP proxy and gross-to-net) and script volume under contracting cycles.

---

FAQs

1) Is MOXEZA a “differentiated” product or a class-substitutable antibiotic?

MOXEZA is an ophthalmic antibiotic within the fluoroquinolone class where substitutability is high and payer contracting largely determines net economics.

2) Why does MOXEZA’s revenue often decline faster than unit volume after generics enter?

Because list price-to-net price compresses quickly through rebates, discounts, and formulary pressure, while volume erosion can lag.

3) What matters more for MOXEZA profitability: price or volume?

Net price typically matters more once rebate intensity rises post-competition; margins can fall even if volumes stabilize.

4) How do contracting cycles affect quarter-to-quarter MOXEZA performance?

Rebate resets and formulary decisions often cause step changes in net revenue even when prescribing behavior changes more gradually.

5) What is the main strategic lever for defending MOXEZA share?

Maintaining preferred formulary status at economically viable rebate levels, supported by dosing convenience and channel execution.

---

References

[1] FDA. MOXEZA (moxifloxacin ophthalmic solution) product information and labeling. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/